Skip to content
TrialScanner

NCT03655613

APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC

Phase 1/Phase 2TerminatedAPLMLead

Registry record

Lead sponsor
Apollomics (Australia) Pty. Ltd.
Conditions
Hepatocellular Carcinoma; Renal Cell Carcinoma
Primary completion
Dec 15, 2021Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03655613 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03655613: APL-501 or Nivolumab in... | TrialScanner